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enly rendered a false-positive diagnosis of 
hepatocellular carcinoma at both CT [5] and 
MRI [6] for lesions that subsequently proved 
to be focal confluent fibrosis at explantation.
The organ allocation policy of the Unit-
ed Network of Organ Sharing based on the 
model for end-stage liver disease gives can-
didates with stage T2 hepatocellular carci-
noma priority for transplantation beyond the 
degree of hepatic decompensation [7]. Be-
cause of the shortage of transplant organs, 
knowledge of the imaging characteristics of 
focal confluent fibrosis is important to avoid 
patients receiving a higher or lower priority 
for a transplant than is necessary. Moreover, 
knowledge of the presence of confluent fi-
brosis is important in planning liver resec-
tion because fibrosis influences the degree of 
liver regeneration [8].
Although the imaging findings of focal 
confluent fibrosis, such as capsule retraction 
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F
ocal confluent fibrosis is com-
monly encountered in patients 
with long-standing cirrhosis, al-
though it has also been described 
in patients with early-stage compensated cir-
rhosis [1]. The process of hepatic parenchy-
ma collapse and replacement with focal fi-
brotic masses has been shown to result in 
corresponding imaging changes at CT and 
MRI [2, 3]. These changes can be summa-
rized as a focal, often wedge-shaped mass 
radiating from the porta hepatis, with either 
overlying capsule retraction or focal flatten-
ing of the capsule, most often involving the 
anterior and medial segment and, less fre-
quently, the posterior segment [2, 3].
Investigators have reported difficulties in 
the MRI diagnosis of biopsy-proven hepato-
cellular carcinomas in cirrhotic liver because 
of the presence of underlying focal confluent 
fibrosis [4]. Other researchers have mistak-
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OBJECTIVE. The objective of this study was to assess the long-term natural history of 
focal confluent fibrosis in cirrhotic liver with CT.
MATERIALS AND METHODS. Two radiologists retrospectively reviewed in consen-
sus 118 liver CT examinations in 26 patients (19 men, seven women; age range, 32–68 years; 
mean age, 50 years) performed over approximately 6 years. Helical CT scans were obtained 
before and 30–35 and 65–70 seconds after injection of 125–150 mL of contrast medium at a 
rate of 4–5 mL/s. Proof of cirrhosis was based on liver transplantation (n = 6), biopsy (n = 
9), or imaging findings (n = 11). The number, location, and attenuation of fibrotic lesions and 
presence of trapped vessels were evaluated. Variation of hepatic retraction associated with the 
development of focal confluent fibrosis lesions was assessed using the ellipsoid volume for-
mula and an arbitrary retraction index.
RESULTS. Each radiologist identified 41 focal confluent fibrosis lesions. All lesions were 
identified by both radiologists. Twelve patients (46%) had a single lesion, 13 (50%) had two 
lesions, and one (4%) had three lesions. Thirty-four (83%) of 41 lesions were located in seg-
ment IV, VII, or VIII. Thirty-two lesions (78%) were hypoattenuating on unenhanced imag-
es, 25 lesions (61%) were hypoattenuating on hepatic arterial phase images, and 20 lesions 
(49%) were isoattenuating on portal venous phase images. Seven lesions (17%) were or be-
came hyperattenuating at follow-up on portal venous phase images. Trapped vessels were 
found in six lesions (15%). The retraction index showed a significant increase over time (r = 
0.423, p ≤ 0.0001).
CONCLUSION. The degree of capsule retraction associated with focal confluent fibro-
sis evolves with time and relates to the natural evolution of cirrhosis.
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and delayed enhancement, have been docu-
mented with both CT and MRI [1–3, 9], the 
process leading to a characteristic imag-
ing finding has not been investigated to our 
knowledge. Because not all patients with con-
fluent fibrosis show characteristic capsule re-
traction, we question whether those without 
this finding may be imaged at an earlier time 
and whether all patients eventually develop 
capsule retraction. Given the difficulties en-
countered by several investigators in the di-
agnosis of hepatocellular carcinoma when 
focal confluent fibrosis was present [4–6], we 
speculate that knowledge of the evolutionary 
process of focal confluent fibrosis would help 
correctly diagnose this entity.
The purpose of this study, therefore, was 
to assess the long-term natural history of fo-
cal confluent fibrosis in the cirrhotic liver 
with serial CT.
Materials and Methods
Institutional Review Board Approval and 
Inclusion Criteria
This was a retrospective study performed in 
a single institution. Institutional review board 
approval was obtained for chart review. All 
abdominal CT reports dictated between January 
1, 1998, and April 30, 2004, containing both the 
terms “confluent” and “fibrosis” in the text were 
retrospectively identified using a computerized 
search of our radiology information system. A 
research assistant and a radiologist reviewed the 
reports and medical records to select patients who 
met the inclusion criteria for this study.
The inclusion criteria were, first, a diagnosis of 
cirrhosis; second, CT performed after IV contrast 
injection; and, third, repeat liver CT performed at 
least once during the study period with an interval 
of 6 months or more between the initial and the 
final CT examinations. The presence of a liver 
tumor was not among the exclusion criteria for 
this study.
Patients
Twenty-six patients fulfilled the inclusion cri-
teria: 19 men and seven women, with an age range 
of 32–68 years (mean age, 50 years). Women 
ranged in age from 40 to 59 years (mean age, 
49 years), and men ranged in age from 32 to 68 
years (mean age, 51 years); this difference was not 
statistically significant (p = 0.547). All patients 
had cirrhosis due to the following underlying 
causes: alcoholism (n = 20); primary sclerosing 
cholangitis (n = 3); and one each of hepatitis 
C, HIV associated with hepatitis C, and HIV 
associated with hepatitis B and C. Diagnosis of 
cirrhosis was based on histology in 15 patients: 
liver transplantation (n = 6) and liver biopsy (n = 
9). In those six patients who underwent liver 
transplantation, the pathologists also confirmed 
the presence of all nine focal confluent fibrosis 
lesions seen at CT. In the remaining 11 patients, 
a clinical diagnosis of cirrhosis was based on a 
combination of imaging findings [10, 11], upper 
endoscopic findings (i.e., esophageal varices or 
congestive gastropathy), abnormal laboratory 
values (i.e., prolonged prothrombin time, de-
creased platelet count, and abnormal serum 
albumin and cholesterol levels, and increased 
total bilirubin and γ-globulin levels), and clinical 
presentation (i.e., cutaneous spider angiomas, 
abdominal subcutaneous portosystemic shunts, 
and mild ascites).
We also reviewed the Child-Pugh classification 
for patients, whether patients had liver neoplasms, 
and any related interventional procedures between 
the initial imaging and follow-up imaging because 
hepatic lesions can develop capsule retraction 
after treatment [12], therefore mimicking focal 
confluent fibrosis.
CT Technique
All CT scans were obtained at our institution 
with a single-detector CT scanner or a 4- or 
16-MDCT scanner (HiSpeed Advantage or 
LightSpeed QX/I, GE Healthcare). In all patients, 
scanning was performed at 120–140 kV and 200–
250 mAs with a 512 × 512 matrix. For single-
detector helical CT, images were obtained with a 
5- to 7-mm collimation and a table pitch of 1:1–
1:1.5. For MDCT, examinations were performed 
with the following parameters: collimation, 2.5 
mm; table speed, 15 mm per rotation; and rotation 
time, 0.8 second. Images were reconstructed at 
5.0-mm intervals. The multiphasic CT protocol 
included images obtained within one breath-hold 
at deep inspiration during the unenhanced phase, 
hepatic arterial dominant phase, and portal venous 
dominant phase. The hepatic arterial and portal 
venous dominant phase scans were initiated at 30–
35 and 65–70 seconds, respectively, after injection 
of a bolus of contrast material. All patients received 
125 or 150 mL of either iothalamate meglumine 
(Conray 60, Mallinckrodt Imaging) or ioversol 
(Optiray 350, Mallinckrodt Imaging) injected IV at 
a rate of 4–5 mL/s with a power injector (OP 100, 
Medrad) through an 18- or 20-gauge catheter in an 
antecubital vein.
Image Analysis
Two radiologists with 25 and 5 years’ experience 
in abdominal imaging reviewed together a total of 
118 examinations (range, 2–9 CT examinations 
per patient; range of follow-up, 3–81 months; 
mean CT follow-up period, 25 months; range of 
time interval between CT studies, 3–12 months; 
mean time interval between CT examinations, 
6 months). The first CT examination during the 
study period (~ 6 years) was considered the initial 
examination, and the most recent CT examination 
was considered the final examination. The radiol-
ogists reviewed the initial CT scans as well as any 
follow-up scans with a PACS (Isite Radiology, 
Philips Healthcare) and evaluated the number, 
segmental location, attenuation, and size of capsule 
retraction associated with focal confluent fibrosis 
lesions. In cases of interobserver disagreement, 
final decisions were reached by means of 
consensus. All measurements were performed 
using settings typically close to a window width 
and window level of 250 and 60 HU, respectively, 
although in selected cases readers subjectively 
used a narrower window.
Focal confluent fibrosis was defined as a peri-
pheral, wedge-shaped area showing isoattenu ation 
or hypoattenuation compared with the adjacent 
liver parenchyma on unenhanced images that was 
associated with focal flattening or concavity of the 
normal convex hepatic contour. The location of 
focal confluent fibrosis was categorized according 
to the hepatic segmentation defined by the 
Couinaud system [13]. The overall attenuation of 
focal confluent fibrosis was defined relative to the 
liver during the same phase (unenhanced, hepatic 
arterial dominant, or portal venous dominant 
phase) of imaging. For each CT examination, two 
radiologists measured together with electronic 
calipers the greatest craniocaudal, transverse, and 
anteroposterior diameters of the areas of capsule 
retraction associated with confluent fibrosis 
lesions. Because coronal images were not obtained 
routinely during the time period of scanning, the 
craniocaudal diameter (height) was calculated by 
multiplying the thickness of the reconstructed CT 
images for the number of the contiguous transverse 
CT sections in which the focal confluent fibrosis 
lesion with associated retraction was detected. 
The transverse diameter (length) was measured as 
the distance between the maximum extent of the 
outer borders of the lesion (i.e., where the liver 
capsule turned from convex to flat or concave). 
Because focal confluent fibrosis lesions were 
visible on several contiguous transverse images, 
the image showing the largest transverse diameter 
was selected for measurement. The anteroposter-
ior diameter depth (width) was calculated on the 
transverse image showing the largest focal con-
fluent fibrosis transverse diameter by measuring 
the maximal anteroposterior distance between the 
deepest point of the focal confluent fibrosis lesion 
and an imaginary convex line joining the non-
retracted liver surface adjacent to the focal 
confluent fibrosis lesion using an assessment of 
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where the normal curvature of the liver margin 
would have been expected to project (Fig. 1). The 
volume of capsule retraction associated with focal 
confluent fibrosis was arbitrarily calculated on the 
basis of the evaluated diameters using the ellip-
soid volume formula: [(product of the three 
measure ments) × 0.523]. These measurements 
were performed on all the serial CT scans for each 
patient, and the results were incorporated on a 
standard spreadsheet.
In addition to the evolution of retraction, other 
secondary signs that may characterize benign 
fibrosis were noted: the presence of trapped vessels 
in the focal confluent fibrosis lesion, defined as 
twisted and crowded vessels seen during the arterial 
or portal phase, and the morphology and evolution 
in shape of the area of hepatic retraction toward the 
porta hepatis associated with the focal confluent 
fibrosis lesion. This area was defined as an apex 
when it described an angle toward the porta hepatis.
Statistical Analysis
Because multiple measurements of the ellipsoid 
volume were performed at irregular time intervals, 
a linear regression analysis with the mixed-effects 
model was used to correlate ellipsoid volume 
with time elapsed since the first CT examination. 
Statistical analysis was performed using the 
Fisher’s exact test for slope regression [14, 15].
Changes in retraction extent measured with an 
arbitrary index (retraction index) ranging from –1 
to 9, in continuous values, were obtained using 
standard linear regression analysis. The following 
equation was used to calculate the retraction index: 
124.34 (a) × elapsed interval in months,
where a is the slope regression coefficient. The 
retraction index was defined as a variation of the 
ellipsoid volume over time. A stable retraction index 
was defined as a change in retraction of ≤ 0.5%.
A classification and regression tree analysis 
performed using the Fisher’s exact test was used 
to build the most efficient classification algorithm 
combining retraction index and time interval. 
Statistical analysis to compare the various clinical 
and demographic factors was performed using the 
Student’s t test. A p value of less than 0.05 was 
considered significant. The unit of measure in our 
statistical analysis was retraction index variation, 
rather than the number of patients or number 
of lesions. All analyses were performed using 
Microsoft Excel 2000 and SPSS software (version 
13, SPSS).
Results
Each radiologist identified 41 focal conflu-
ent fibrosis lesions. Interpretation discrepan-
cies between the two readers were minor and 
were resolved by consensus. Twelve patients 
(46%) had a single lesion, 13 patients (50%) 
had two lesions (Fig. 2), and one patient (4%) 
had three lesions. Thirty-four (83%) of 41 le-
sions were located in segment IV, VII, or 
VIII (Figs. 2–5). Table 1 shows the segmen-
tal locations of the lesions. Table 2 shows 
the attenuation of the lesions in the different 
phases of contrast enhancement.
Trapped vessels were found in six lesions, 
each in a different patient (Fig. 4). In five le-
sions the two radiologists noted a narrower 
apex in the retracted area toward the porta 
Fig. 1—CT scan shows measured parameters: 
dotted line = transverse diameter (length), straight 
line = anteroposterior diameter (depth), curved line 
= imaginary convex line joining nonretracted liver 
surface adjacent to focal confluent fibrosis lesion 
that projects expected prior normal liver capsule 
course and that is used to measure anteroposterior 
diameter (see text).
A
Fig. 2—61-year-old man with primary sclerosing cholangitis–related cirrhosis and focal confluent fibrosis. 
A and B, Axial unenhanced (A) and contrast-enhanced (B) CT scans obtained during arterial phase show low 
attenuation peripherally in segments VIII and IV. No capsule retraction is seen. 
C and D, Unenhanced (C) and portal venous phase (D) CT scans obtained through same level as A and B 2 years 
after A and B show focal confluent fibrosis lesions with interval development of marked atrophy and overlying 
capsule retraction (arrowheads, C) in segments IV and VIII. Lesion in segment VIII (arrow, D) homogeneously 
enhances. Retraction volume for segment VIII lesion was 13.8 cm3. Note grossly lobulated contours of liver, as 
typically seen in primary sclerosing cholangitis. Moderate amount of perihepatic ascites (a) is present. This 
patient underwent liver transplantation and diagnosis of focal confluent fibrosis was confirmed at histology.
B
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hepatis, and in all cases the apex had become 
flattened at follow-up CT (Fig. 5).
At the initial CT (time 0), 16 patients al-
ready had some capsule retraction in 27 le-
sions, whereas in 10 patients the area of 
fibrosis was not associated with capsule re-
traction in 14 lesions. At follow-up CT, seri-
al measurements showed that an increase of 
the retraction index was never > 52.7% (cor-
responding mean volume decrease = 13.8 ± 
7.1 [SD] cm3) and that the number of lesions 
in which we observed an increase of retrac-
tion was never > 40% over each time inter-
val (Table 3). The retraction index showed 
a progressively moderate but overall signif-
icant increase over time (Fig. 5), and cap-
sule retraction developed in all lesions. In 
one patient, capsule retraction appeared to 
have decreased at follow-up because of the 
increasing shrinkage and volume loss of the 
adjacent liver parenchyma due to progressive 
lobar involvement. Table 3 shows the varia-
tions of the retraction index with time. Fig-
ure 6 shows the overall significant increase 
of retraction index over time.
In 10 patients, cirrhosis was Child-Pugh 
class A, one of whom had class A/B cirrho-
sis. In 13 patients, cirrhosis was Child-Pugh 
class B, one of whom had class B/C cirrho-
sis. In three patients, cirrhosis was Child-
Pugh class C. Two of 26 (8%) patients had 
a single hepatocellular carcinoma: One was 
treated with transarterial chemoemboliza-
tion and the other with transarterial radia-
tion therapy with 90Y incorporated into glass 
microspheres (TheraSphere, MDS Nordion). 
In both cases, the hepatocellular carcinoma 
lesions were located in different segments 
of the liver from that of the focal conflu-
ent fibrosis lesions. The patient treated with 
transarterial chemoembolization underwent 
liver transplantation, and the pathologist 
confirmed the diagnosis of focal confluent fi-
brosis at explantation.
Discussion
In this study, we found that there is a pro-
gressively moderate increase over time of 
the capsule retraction that accompanies the 
development of focal confluent fibrosis. The 
fact that serial measurements showed an in-
crease of the retraction index that was nev-
er > 52.7% (the corresponding mean volume 
decrease would have been 13.8 ± 7.1 [SD] 
cm3) and that the number of lesions in which 
we observed an increase of the retraction was 
never > 40% might be a consequence of the 
inclusion criteria of our study. Indeed, only 
14 of 41 focal confluent fibrosis lesions did 
not show retraction at initial CT, whereas the 
remaining 27 already presented capsule re-
traction of variable severity. An explanation 
for this result could be that capsule retrac-
tion possibly starts developing in early-stage 
compensated cirrhosis [1] and that in end-
stage cirrhosis the architectural distortion 
evolves into diffuse shrinkage, which might 
A
Fig. 3—32-year-old man with alcoholic cirrhosis and focal confluent fibrosis.
A, Axial arterial phase CT scan shows irregular, mottled liver enhancement with no evident capsule retraction. Small amount of perihepatic ascites (a) is present. 
B, Axial unenhanced CT scan obtained 1 year after A through same level as A shows lesion (asterisk) of lower attenuation than adjacent liver parenchyma involving 
segment IV and mild retraction (3.3 cm3 of volume retraction) of liver capsule (arrowhead), which is typical of focal confluent fibrosis. 




Fig. 4—Transverse CT scans obtained in 52-year-old 
man with hepatitis C–related cirrhosis and focal 
confluent fibrosis. 
A, Unenhanced scan shows wedge-shaped lesion 
(asterisk) of lower attenuation than adjacent liver 
parenchyma in segment VIII. Deep retraction of liver 
capsule (arrowhead) is seen. 
B, Arterial phase scan shows trapped vessels 
(arrows) in focal confluent fibrosis lesions. Volume 
loss is 24.8 cm3.
B
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result in a reduction of capsule retraction or, 
as described in one of our cases, in its dis-
appearance. Despite the relative heterogene-
ity of our study population and results, the 
retraction index showed an overall signifi-
cant increase over time. We did not perform 
a subgroup analysis of the 14 focal conflu-
ent fibrosis lesions that did not show retrac-
tion at initial CT; therefore, we believe that a 
prospective study evaluating the morphology 
evolution of a larger number of cirrhotic liv-
ers at the initial stage—that is, when capsule 
retraction has not developed yet—would be 
beneficial in further clarifying this issue.
Ohtomo et al. [2] found that five of 49 le-
sions of wedge-shaped confluent fibrosis 
were not associated with capsule retraction. 
The percentages of cases with atrophy or re-
traction reported by those authors [2] reflect, 
however, only one point in time. Our study 
is the first, to our knowledge, to show the ef-
fects over time. In our study, even the 14 fo-
cal confluent fibrosis lesions that did not show 
retraction at the initial CT eventually devel-
oped retraction at follow-up CT. Our results, 
when considered sequentially, suggest that 
a higher percentage of cases will show this 
finding. We hypothesize that the five cases 
not associated with retraction described by 
Ohtomo et al. most likely would have eventu-
ally developed it if followed further.
In our experience, wedge-shaped areas of 
hypoattenuation are frequently encountered 
at CT in the surveillance of the cirrhotic liver 
performed every 6–12 months [16] and do 
not warrant biopsy when worrisome findings 
for hepatocellular carcinoma, such as en-
hancement in the arterial phase, washout in 
the delayed phase, and bulging of the liver 
capsule, are absent. Development of capsule 
retraction over time and the associated ancil-
lary findings that we report here are an addi-
tional clue toward the diagnosis of focal con-
fluent fibrosis.
In our study, we found a typical evolving 
morphologic pattern of the retracted area as-
sociated with focal confluent fibrosis. In ad-
dition to developing or increasing capsule 
retraction peripherally, the central apex of fi-
brosis also showed characteristic evolution-
ary changes. In five cases, the central apex of 
involvement widened so that rather than ap-
A
Fig. 5—48-year-old woman with alcoholic cirrhosis and focal confluent fibrosis.
A, Initial axial unenhanced CT scan shows area of retraction has shape of triangle with apex (arrowhead) oriented toward porta hepatis. Note transjugular intrahepatic 
portosystemic shunt (T). 
B, Axial contrast-enhanced CT scan obtained 1 year after A shows apex has become slightly flattened (arrowhead).  Volume loss is 2.1 cm3. 
C, Axial contrast-enhanced CT scan obtained 5 years after A shows further flattening at apex compared with A and B and area of retraction has become polygonal-
shaped. Volume loss is 2.7 cm3.
CB
TABLE 3: Variation of Retraction Index with Time
Time of Follow-Up 
(mo)
No. (%) of Lesions Average (Range)  
of Increase in 
Retraction Index 
(%)b
Mean Volume  






< 24 24 (59) 17 (41)  1 (0.5–2.5)  0.3 (± 0.1)
24–40 27 (66) 14 (34)  7 (6.9–7.9)  2 (± 0.2)
40–60 34 (83) 7 (17)  52 (51.5–52.7)  13.8 (± 7.1)
> 60 36 (88) 5 (12)  17 (16.8–18.9)  2.2 (± 0.4)
aRetraction index is an arbitrary index used to measure variation of hepatic retraction associated with 
development of focal confluent fibrosis lesion.
bIn lesions that retracted.
TABLE 1: Segmental Location of 
Focal Confluent Fibrosis 
Lesions







TABLE 2: Attenuation of the Focal Confluent Fibrosis Lesions in the  
Different Phases of Contrast Enhancement
Phase Hypoattenuating Isoattenuating Hyperattenuating
Unenhanced phase 32 9 0
Hepatic arterial phasea 25 15 0
Portal venous phase 19 20b 2
aIn one case, arterial phase was not obtained.
bFive isoattenuating lesions became hyperattenuating at follow-up CT.
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pearing wedge-shaped, the affected area be-
came flattened centrally. Although we did not 
specifically analyze the time frame of evolv-
ing changes in this subgroup of patients, we 
believe that an interval follow-up of 6–12 
months is adequate in these patients. An 
awareness of these changes over time would 
probably further aid in differentiating these 
lesions from hepatocellular carcinoma.
Twenty (77%) of our 26 patients had alco-
holic cirrhosis, which is in accordance with 
the findings of Ohtomo et al. [2]: They found 
that alcohol abuse was also the type of cir-
rhosis most commonly associated with fo-
cal confluent fibrosis. Eighty-three percent 
of the lesions in our study were located in 
segment IV, VII, or VIII, which is also in ac-
cordance with the results of Ohtomo et al. [2, 
3] that showed most focal fibrosis lesions in-
volved the medial segment of the left lobe or 
the anterior right lobe.
Seven lesions were or became hyperdense 
at follow-up CT on portal venous phase imag-
ing that were not enhancing on arterial phase 
imaging. This pattern of enhancement might 
be due to the initial retaining of contrast mate-
rial by the fibrous stroma. Some authors [17, 
18] have recently emphasized the importance 
of adding the delayed phase to the imaging 
protocol for the study of the cirrhotic liver, 
whereas others [19, 20] have shown that un-
enhanced images are of limited value. In this 
study we did not obtain delayed scans rou-
tinely because these articles were published 
after we began collecting our cases, so we do 
not think that we were performing a subop-
timal scanning technique at that time. Nev-
ertheless, we believe that the delayed phase 
is a valuable adjunct technique; therefore, 
in our daily practice, we have now modified 
our CT liver protocol accordingly. If we had 
performed delayed imaging in the patients in 
this study, we speculate that the enhancement 
would have been stronger [1], similar to the 
process of contrast retention in the fibrous 
stroma of cholangiocarcinoma seen on delay 
phase imaging [21]. Fortunately, with the ex-
ception of patients with primary sclerosing 
cholangitis, cholangiocarcinoma is uncom-
mon with cirrhosis [22]. Because delayed 
phase enhancement and capsule retraction 
are imaging features commonly encountered 
in both cholangiocarcinoma and focal conflu-
ent fibrosis, a confident differential diagno-
sis with imaging alone might not be possible 
in patients with primary sclerosing cholang-
itis–related cirrhosis and therefore a biopsy 
should be performed.
We found trapped vessels in six lesions. 
Trapped vessels are likely the consequence 
of liver parenchymal collapse and subse-
quent fibrosis that does not displace vessels, 
but surrounds existing vessels. These vessels 
are often multiple and are crowded together 
because of the retraction and can be misdi-
agnosed as hepatocellular carcinoma if mis-
taken for tumor enhancement or tumor neo-
vascularity. In addition, the absence of the 
bulging effect, usually associated with an un-
treated malignant lesion at the capsule sur-
face, and absence of washout in the portal ve-
nous or delayed phase as compared with the 
surrounding liver are the key findings that al-
low differential diagnosis of hepatocellular 
carcinoma. The trapping of vessels within the 
collapsed parenchyma can be an aid to char-
acterize fibrosis because most malignant le-
sions will displace vessels. Most often these 
crowded, trapped vessels have a different ap-
pearance than the previously described arteri-
al phase enhancement that can be associated 
with confluent fibrosis. The small number of 
patients, after dividing them into subgroups, 
prevented us from analyzing whether a spe-
cific cause was more frequently associated 
with the occurrence of trapped vessels, and 
whether trapped vessels were observed more 
commonly in patients with a single lesion or 
multiple lesions. We are not aware of previ-
ous descriptions of trapped vessels and evo-
lution toward an apex morphology found in 
association with focal confluent fibrosis.
In one of the two patients with hepatocel-
lular carcinoma who underwent interven-
tional treatment, the pathologist confirmed 
the diagnosis of focal confluent fibrosis at ex-
plantation. For the other patient with hepato-
cellular carcinoma, we do not have patholog-
ic proof of the focal confluent fibrosis lesion. 
However, in this patient the hepatocellular 
carcinoma and the focal confluent fibrosis le-
sion were located in different segments. In 
previous studies in which investigators ex-
amined resected specimens after an inter-
ventional treatment, they have described ex-
tensive necrosis of the tumor and sparing of 
adjacent hepatic parenchyma [23]. With the 
same reasoning, we believe it is unlikely that 
the area we diagnosed as focal confluent fi-
brosis was retracted hepatic parenchyma sec-
ondary to the interventional treatment.
Our study has several potential limitations. 
First, the difficulty in obtaining accurate mea-
surements of capsule retraction on transverse 
CT scans alone might lead to inaccuracies in 
assessing for interval change, which might be 
better observed on coronal reconstructions as 
commonly performed today. Moreover, the 
measurements were obtained by two readers 
working together, whereas a more accurate 
method would have been to obtain an average 
value of measurements calculated by three 
different readers. Second, the diagnosis of 
cirrhosis was established with pathology in 
only 15 patients, and the diagnosis of focal 
confluent fibrosis was established with pa-
thology in only nine cases occurring in the 
six patients who underwent liver transplanta-
tion. In the remaining cases, biopsy of the cir-
rhotic liver was performed randomly and was 
not directed to the area of fibrosis. Third, ours 
was a retrospective study; therefore, some se-
lection bias may be present. For example, the 
search methods we used may not have identi-
fied all patients with focal confluent fibrosis 
lesions who underwent scanning during the 
specified time period, particularly if the orig-

























and regression line for 
retraction index of 41 
focal confluent fibrosis 
lesions measured in 26 
patients. Regression 
line shows overall 
significant increase of 
retraction index over 
time.
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the term “confluent” in the official report. 
Fourth, the chosen 6-month interval is arbi-
trary. According to our referring clinicians’ 
protocol, CT evaluations were performed ev-
ery 6 months in patients with cirrhosis for he-
patocellular carcinoma surveillance. Fifth, 
the time for follow-up examination was not 
standardized, and it was not possible to as-
sess accurately the time interval between the 
beginning liver disease and imaging. Sixth, 
our CT protocol was not uniform because of 
the remarkable advancements in CT hard-
ware and software in the past few years and 
because our study was retrospective. Seventh, 
we did not correlate the rate of retraction with 
liver function test results or other clinical pa-
rameters, and it will be of interest in future 
studies to investigate whether these two fea-
tures are correlated. Eighth, the measure-
ments of the depth of retraction might have 
been affected by the progressive shrinkage 
and rotation of different liver segments ob-
served during the progression of the disease.
In conclusion, the results of our study 
show that the degree of capsule retraction as-
sociated with focal confluent fibrosis evolves 
with time and relates to the natural evolu-
tion of cirrhosis. In addition, the presence of 
crowded, trapped vessels within confluent fi-
brosis can occasionally be seen. Understand-
ing of this process may aid in differentiating 
this lesion from hepatocellular carcinoma.
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